Exane Derivatives raised its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 29.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,658 shares of the biopharmaceutical company’s stock after acquiring an additional 1,055 shares during the period. Exane Derivatives’ holdings in Bristol-Myers Squibb were worth $286,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in BMY. Atlantic Trust LLC bought a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $111,000. Massey Quick Simon & CO. LLC grew its holdings in shares of Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the last quarter. Blue Chip Partners Inc. grew its holdings in shares of Bristol-Myers Squibb by 0.7% during the second quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock worth $120,000 after purchasing an additional 15 shares during the last quarter. Horan Capital Advisors LLC. bought a new stake in shares of Bristol-Myers Squibb during the third quarter worth about $122,000. Finally, BDO Wealth Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the second quarter worth about $123,000. Hedge funds and other institutional investors own 69.82% of the company’s stock.
In other Bristol-Myers Squibb news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction that occurred on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the transaction, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at $585,033.24. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Theodore R. Samuels II purchased 4,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was acquired at an average cost of $62.30 per share, for a total transaction of $249,200.00. Following the completion of the purchase, the director now owns 22,000 shares of the company’s stock, valued at approximately $1,370,600. The disclosure for this purchase can be found here. 0.23% of the stock is owned by insiders.
Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The company had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. During the same period in the previous year, the firm earned $0.63 earnings per share. analysts predict that Bristol-Myers Squibb Co will post 3.21 EPS for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, February 1st. Investors of record on Friday, January 5th were paid a $0.40 dividend. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.35%. The ex-dividend date of this dividend was Thursday, January 4th. Bristol-Myers Squibb’s payout ratio is currently 271.19%.
BMY has been the topic of several research reports. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a report on Thursday, November 2nd. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a report on Tuesday, January 16th. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the stock a “buy” rating in a report on Tuesday, December 5th. Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the stock a “sell” rating in a report on Monday, December 11th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $66.18.
COPYRIGHT VIOLATION WARNING: “Bristol-Myers Squibb Co (BMY) Holdings Lifted by Exane Derivatives” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.tickerreport.com/banking-finance/3222884/bristol-myers-squibb-co-bmy-holdings-lifted-by-exane-derivatives.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.